Duration of Response and Progression-Free Survival with Sonidegib 200 Mg Once Daily Until Disease Progression or Start of New Antineoplastic Therapy in Patients with Locally Advanced Basal Cell Carcinoma: Results of the 42-Month, Randomized, Double-Blind

Main Article Content

Michael Migden
John Lear
Nicholas Squittieri
Li Liu
Alexander Guminski
Reinhard Dummer

Keywords

Basal Cell carcinoma, Sonidegib, duration of response

Abstract

Abstract not available.

References

1) Xiang F, et al. JAMA Dermatol. 2014; 150:1063–71

2) Asgari MM, et al. JAMA Dermatol. 2015; 151:976–81

3) Amici JM, et al. Eur J Dermatol. 2015; 25:586–94

4) Lear JT, et al. Br J Cancer. 2014; 111:1476–81

5) Cortes JE, et al. Cancer Treat Rev. 2019; 76:41–50

6) Kim JYS, et al. J Am Acad Dermatol. 2018; 78:540–59

7) Odomzo (sonidegib) [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2017

8) European Medicines Agency. Summary of Product Characteristics, WC500188762

9) Swissmedic, Authorization Number 65065, 2015

10) Australian Government Department of Health, ARTG 292262

11) Migden MR, et al. Lancet Oncol. 2015; 16:716–28

12) Migden MR, et al. J Clin Oncol. 2018; 36:Suppl abstr 9551

13) Lear JT, et al. J Eur Acad Dermatol Venereol. 2018; 32:372–81

14) Dummer R, et al. J Am Acad Dermatol. 2016; 75:113–25.E115

15) Dummer R, et al. Br J Dermatol. 2019; 10.1111/bjd.18552

16) Eisenhauer EA, et al. Eur J Cancer. 2009; 45 (2): 228–47

17) World Health Organization. http://whqlibdoc.who.int/offset/WHO_OFFSET_48.pdf

18) National Cancer Institute. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf.